Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study
Background Osimertinib is recommended for non‐small cell lung cancer (NSCLC) patients with EGFR mutation; however, it is unclear whether body size variables affect the efficacy of osimertinib in such patients. This study assessed the potential effect of body surface area (BSA) and body mass index (B...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-04-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13018 |
| _version_ | 1827965835510022144 |
|---|---|
| author | Taihei Ono Satoshi Igawa Takahiro Ozawa Masashi Kasajima Mikiko Ishihara Yasuhiro Hiyoshi Seiichiro Kusuhara Noriko Nishinarita Tomoya Fukui Masaru Kubota Jiichiro Sasaki Mitsufuji Hisashi Masato Katagiri Katsuhiko Naoki |
| author_facet | Taihei Ono Satoshi Igawa Takahiro Ozawa Masashi Kasajima Mikiko Ishihara Yasuhiro Hiyoshi Seiichiro Kusuhara Noriko Nishinarita Tomoya Fukui Masaru Kubota Jiichiro Sasaki Mitsufuji Hisashi Masato Katagiri Katsuhiko Naoki |
| author_sort | Taihei Ono |
| collection | DOAJ |
| description | Background Osimertinib is recommended for non‐small cell lung cancer (NSCLC) patients with EGFR mutation; however, it is unclear whether body size variables affect the efficacy of osimertinib in such patients. This study assessed the potential effect of body surface area (BSA) and body mass index (BMI) on osimertinib chemotherapy in patients with T790M‐positive advanced NSCLC who progress on prior EGFR‐tyrosine kinase inhibitors (TKIs). Methods We conducted a prospective observational cohort study. Median BSA and BMI were used as cut‐off values to evaluate the impact of body size variables on osimertinib chemotherapy. Results The median BSA and BMI of 47 patients were 1.50 m2 and 21.5 kg/m2, respectively. Clinical outcomes did not significantly differ between the high and low BSA groups, with response rates of 59.1% and 56.0% (P = 0.83) and progression‐free survival (PFS) of 7.6 and 9.1 months (P = 0.69), respectively. Similarly, there were no significant differences between the high and low BMI groups relative to response rates, which were 60.8% and 54.1% (P = 0.64), respectively, and PFS, which was 7.6 months in both groups (P = 0.38). No significant differences were observed among toxicity profiles in relation to BSA or BMI. Multivariate analysis identified better performance status, young age, and EGFR exon 19 deletion as independent favorable predictors of PFS. Conclusion The efficacy of osimertinib does not significantly vary relative to body size variables of patients with T790M‐positive NSCLC who progress on prior EGFR‐TKIs. |
| first_indexed | 2024-04-09T17:39:38Z |
| format | Article |
| id | doaj.art-762b2755eaa24337811d3fbfc457d213 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-09T17:39:38Z |
| publishDate | 2019-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-762b2755eaa24337811d3fbfc457d2132023-04-17T06:34:28ZengWileyThoracic Cancer1759-77061759-77142019-04-0110488088910.1111/1759-7714.13018Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational studyTaihei Ono0Satoshi Igawa1Takahiro Ozawa2Masashi Kasajima3Mikiko Ishihara4Yasuhiro Hiyoshi5Seiichiro Kusuhara6Noriko Nishinarita7Tomoya Fukui8Masaru Kubota9Jiichiro Sasaki10Mitsufuji Hisashi11Masato Katagiri12Katsuhiko Naoki13Department of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanResearch and Development Center for New Medical Frontiers Kitasato University School of Medicine Sagamihara‐City JapanKitasato University School of Nursing Sagamihara‐City JapanSchool of Allied Health Sciences Kitasato University Sagamihara‐City JapanDepartment of Respiratory Medicine Kitasato University School of Medicine Sagamihara‐City JapanBackground Osimertinib is recommended for non‐small cell lung cancer (NSCLC) patients with EGFR mutation; however, it is unclear whether body size variables affect the efficacy of osimertinib in such patients. This study assessed the potential effect of body surface area (BSA) and body mass index (BMI) on osimertinib chemotherapy in patients with T790M‐positive advanced NSCLC who progress on prior EGFR‐tyrosine kinase inhibitors (TKIs). Methods We conducted a prospective observational cohort study. Median BSA and BMI were used as cut‐off values to evaluate the impact of body size variables on osimertinib chemotherapy. Results The median BSA and BMI of 47 patients were 1.50 m2 and 21.5 kg/m2, respectively. Clinical outcomes did not significantly differ between the high and low BSA groups, with response rates of 59.1% and 56.0% (P = 0.83) and progression‐free survival (PFS) of 7.6 and 9.1 months (P = 0.69), respectively. Similarly, there were no significant differences between the high and low BMI groups relative to response rates, which were 60.8% and 54.1% (P = 0.64), respectively, and PFS, which was 7.6 months in both groups (P = 0.38). No significant differences were observed among toxicity profiles in relation to BSA or BMI. Multivariate analysis identified better performance status, young age, and EGFR exon 19 deletion as independent favorable predictors of PFS. Conclusion The efficacy of osimertinib does not significantly vary relative to body size variables of patients with T790M‐positive NSCLC who progress on prior EGFR‐TKIs.https://doi.org/10.1111/1759-7714.13018Body mass indexbody surface areanon‐small cell lung carcinomaosimertinibprogression‐free survival |
| spellingShingle | Taihei Ono Satoshi Igawa Takahiro Ozawa Masashi Kasajima Mikiko Ishihara Yasuhiro Hiyoshi Seiichiro Kusuhara Noriko Nishinarita Tomoya Fukui Masaru Kubota Jiichiro Sasaki Mitsufuji Hisashi Masato Katagiri Katsuhiko Naoki Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study Thoracic Cancer Body mass index body surface area non‐small cell lung carcinoma osimertinib progression‐free survival |
| title | Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study |
| title_full | Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study |
| title_fullStr | Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study |
| title_full_unstemmed | Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study |
| title_short | Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study |
| title_sort | evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non small cell lung cancer harboring an egfr mutation a prospective observational study |
| topic | Body mass index body surface area non‐small cell lung carcinoma osimertinib progression‐free survival |
| url | https://doi.org/10.1111/1759-7714.13018 |
| work_keys_str_mv | AT taiheiono evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT satoshiigawa evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT takahiroozawa evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT masashikasajima evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT mikikoishihara evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT yasuhirohiyoshi evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT seiichirokusuhara evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT norikonishinarita evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT tomoyafukui evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT masarukubota evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT jiichirosasaki evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT mitsufujihisashi evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT masatokatagiri evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy AT katsuhikonaoki evaluationofosimertinibefficacyaccordingtobodysurfaceareaandbodymassindexinpatientswithnonsmallcelllungcancerharboringanegfrmutationaprospectiveobservationalstudy |